Cipla

The head of Cipla, a $ 325-million dollar Indian pharmaceutical companies and suppliers of low-cost AIDS drugs in South Africa, has to decide what to do about Cipla future. With India ready to enforce international patents in just two years, much of Cipla product line was unmarketable (assuming that it protected on product patents in developed countries based). Describes role Cipla force global pharmaceutical companies to lower their prices for AIDS drugs.

The head of Cipla, a $ 325-million dollar Indian pharmaceutical companies and suppliers of low-cost AIDS drugs in South Africa, has to decide what to do about Cipla future. With India ready to enforce international patents in just two years, much of Cipla product line was unmarketable (assuming that it protected on product patents in developed countries based). Describes role Cipla force global pharmaceutical companies to lower their prices for AIDS drugs.
«Hide

from
Rohit Deshpande,
Laura Winig
Source: Harvard Business School
21 pages.
Publication Date: Jun 23, 2003. Prod #: 503085-PDF-ENG
Cipla HBR case solution